channel 7 parkinson, page-10

My understanding of a double blinded trial is that the researchers have access to the same data at the same time as in an open label study (of course without knowledge of who received the sham surgery). The researchers will conduct their assessment in the same way as in an open label study and sign off on their findings prior to unbinding. All the analysis and assessment will be completed prior to unbinding, where following the unbinding the researchers are then able to review (but not amend) their findings.

If this is correct we could expect release of top line results by mid November, as all analysis will be complete by the end of October.